[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Gri Bio Inc (GRI)

Gri Bio Inc (GRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,175
  • Shares Outstanding, K 2,186
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,960 K
  • EBIT $ -10 M
  • EBITDA $ -10 M
  • 60-Month Beta -1.25
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.94
  • Number of Estimates 2
  • High Estimate $-0.93
  • Low Estimate $-0.95
  • Prior Year $-35.85
  • Growth Rate Est. (year over year) +97.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4100 +36.52%
on 08/07/26
2.5500 -24.51%
on 08/11/26
+0.5450 (+39.49%)
since 07/31/26
3-Month
1.3600 +41.54%
on 07/31/26
2.5500 -24.51%
on 08/11/26
-0.0850 (-4.23%)
since 06/02/26
52-Week
1.3600 +41.54%
on 07/31/26
80.3600 -97.60%
on 09/11/25
-37.2750 (-95.09%)
since 09/02/25

Most Recent Stories

More News
GRI Bio Featured in "Why Now" On-Demand Video Webcast

Video webcast now available here LA JOLLA, CA, Aug. 27, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...

GRI : 1.9250 (+0.79%)
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs

Nine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?

AKTX : 9.70 (-6.46%)
ERNA : 4.72 (+8.39%)
OTLK : 0.6228 (-0.05%)
AIM : 0.2287 (-3.09%)
CNSP : 5.91 (+0.34%)
NVNO : 11.55 (+5.19%)
DARE : 0.7743 (+0.53%)
GRI : 1.9250 (+0.79%)
MBRX : 0.6831 (+5.09%)
GRI Bio Featured in "Why Now" On-Demand Video Webcast

Video webcast now available  here LA JOLLA, CA, Aug. 27, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative...

GRI : 1.9250 (+0.79%)
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

LA JOLLA, CA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic...

GRI : 1.9250 (+0.79%)
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

LA JOLLA, CA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and...

GRI : 1.9250 (+0.79%)
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity LA JOLLA, CA, June 18,...

GRI : 1.9250 (+0.79%)
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity LA JOLLA, CA, June 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc....

GRI : 1.9250 (+0.79%)
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here LA JOLLA, CA, May 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio,...

GRI : 1.9250 (+0.79%)
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here LA JOLLA, CA, May 18,...

GRI : 1.9250 (+0.79%)
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621...

ARM : 233.26 (-0.66%)
GRI : 1.9250 (+0.79%)

Business Summary

GRI Bio Inc. is a clinical stage biopharmaceutical company which focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio Inc., formerly known as Vallon Pharmaceuticals Inc., is based in PHILADELPHIA, PA.

See More

Key Turning Points

3rd Resistance Point 2.1200
2nd Resistance Point 2.0500
1st Resistance Point 1.9800
Last Price 1.9250
1st Support Level 1.8400
2nd Support Level 1.7700
3rd Support Level 1.7000

See More

52-Week High 80.3600
Fibonacci 61.8% 50.1820
Fibonacci 50% 40.8600
Fibonacci 38.2% 31.5380
Last Price 1.9250
52-Week Low 1.3600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.